Accession Number:

AD1105402

Title:

89Zr-Trastuzumab-PET, Rapid Autopsies, and Patient Derived Xenografts to Determine the Extent of Clonal Evolution in Treatment Refractory HER2+ Gastric Cancer

Descriptive Note:

[Technical Report, Final Report]

Corporate Author:

SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK

Personal Author(s):

• Lewis, Jason

Report Date:

2019-12-01

Pagination or Media Count:

22

Abstract:

Trastuzumab, an FDA approved monoclonal antibody that binds to the extracellular domain of HER2, is the standard of care for these patients. However, after an initial response secondary resistance invariably ensues. The molecular basis of therapeutic resistance in HER2-positive EG cancer remains unknown and, until now, no other HER2-directed therapy has shown clinical efficacy in patients with trastuzumab refractory EG cancer.

Descriptors:

• cell physiological processes
• medical personnel
• therapy
• neoplasms
• standards
• tissues
• resistance
• xenografts
• mass spectrometry
• personal information managers
• proteins
• x-ray computed tomography
• abstracts
• biomedical research
• cancer
• cell line
• chemotherapy
• data analysis
• department of defense
• disease attributes

Subject Categories:

• Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]